AR005434A1 - Imidazoles sustituidos por cicloalquilos, un procedimiento para su preparacion, composicion farmaceutica que los comprende, uso de los mismos parala manufactura de un medicamento. - Google Patents

Imidazoles sustituidos por cicloalquilos, un procedimiento para su preparacion, composicion farmaceutica que los comprende, uso de los mismos parala manufactura de un medicamento.

Info

Publication number
AR005434A1
AR005434A1 ARP970100105A ARP970100105A AR005434A1 AR 005434 A1 AR005434 A1 AR 005434A1 AR P970100105 A ARP970100105 A AR P970100105A AR P970100105 A ARP970100105 A AR P970100105A AR 005434 A1 AR005434 A1 AR 005434A1
Authority
AR
Argentina
Prior art keywords
cycloalkyl
manufacture
preparation
pharmaceutical composition
same
Prior art date
Application number
ARP970100105A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR005434A1 publication Critical patent/AR005434A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Detergent Compositions (AREA)

Abstract

Un compuesto imidazol sustituído por cicloalquilo, que comprende la fórmula (I) en la cual R1 es 4 piridilo, pirimidinilo, quinolilo, isoquinolinilo,quinazolin-4-ilo, 1-imidazolilo o 1-bencimidazolilo, anillo que está sustituído tal como figura enla memoria descriptiva; R4 es fenilo, naft-1-ilo onaft-2-ilo, o un heteroarilo, que está sustituído opcionalmente con 1 o 2 sustituyentes, cada uno de los cuales se selecciona independientemente tal comofigura en la memoria descriptiva. R2 esun cicloalquilo C3-7opcionalmente sustituído, o cicloalquil C3-7-alquilo C1-10; o una de sus salesfarmacéutiamente aceptables, un procedimiento para su preparación, composición farmacéutica que los compende, uso de los mismos para lamanufactura de unmedicamento para la inhibición de la síntesis de prostaglandinas endoperóxido- sintasa-2-(PGHS-2).
ARP970100105A 1996-01-11 1997-01-10 Imidazoles sustituidos por cicloalquilos, un procedimiento para su preparacion, composicion farmaceutica que los comprende, uso de los mismos parala manufactura de un medicamento. AR005434A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1001096P 1996-01-11 1996-01-11

Publications (1)

Publication Number Publication Date
AR005434A1 true AR005434A1 (es) 1999-06-23

Family

ID=21743297

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970100105A AR005434A1 (es) 1996-01-11 1997-01-10 Imidazoles sustituidos por cicloalquilos, un procedimiento para su preparacion, composicion farmaceutica que los comprende, uso de los mismos parala manufactura de un medicamento.

Country Status (24)

Country Link
US (1) US6329526B1 (es)
EP (1) EP0889726B1 (es)
JP (1) JP2000503304A (es)
CN (1) CN1213305A (es)
AP (1) AP9700912A0 (es)
AR (1) AR005434A1 (es)
AT (1) ATE276248T1 (es)
AU (1) AU715315B2 (es)
BR (1) BR9708149A (es)
CZ (1) CZ218198A3 (es)
DE (1) DE69730704T2 (es)
ES (1) ES2229335T3 (es)
HU (1) HUP9901233A2 (es)
ID (1) ID18759A (es)
IL (1) IL125224A0 (es)
MA (1) MA24055A1 (es)
MX (1) MX9805628A (es)
NO (1) NO983182L (es)
NZ (1) NZ330889A (es)
PL (1) PL327939A1 (es)
TR (1) TR199801350T2 (es)
UY (1) UY24434A1 (es)
WO (1) WO1997025048A1 (es)
ZA (1) ZA97173B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
US5756499A (en) * 1996-01-11 1998-05-26 Smithkline Beecham Corporation Substituted imidazole compounds
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
JP2000507558A (ja) * 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
WO1997035855A1 (en) * 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP1019394A1 (en) 1997-05-22 2000-07-19 G.D. Searle & Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US20020156104A1 (en) 1997-06-13 2002-10-24 Jerry L. Adams Novel pyrazole and pyrazoline substituted compounds
WO1998057966A1 (en) 1997-06-19 1998-12-23 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
WO1999001452A1 (en) 1997-07-02 1999-01-14 Smithkline Beecham Corporation Novel cycloalkyl substituted imidazoles
JP2001518507A (ja) 1997-10-08 2001-10-16 スミスクライン・ビーチャム・コーポレイション 新規シクロアルケニル置換化合物
WO1999032121A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
US6096899A (en) * 1998-04-14 2000-08-01 The Regents Of The University Of Michigan Cylic imidazole compounds having relatively low hydrogen content and relatively high nitrogen content and polymers formed therefrom
GB9809869D0 (en) * 1998-05-09 1998-07-08 Medical Res Council Inhibition of protein kinases
HUP0102058A3 (en) 1998-05-22 2002-05-28 Smithkline Beecham Corp Novel 2-alkyl substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and their use
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
EP1112070B1 (en) 1998-08-20 2004-05-12 Smithkline Beecham Corporation Novel substituted triazole compounds
DE69914357T2 (de) 1998-11-04 2004-11-11 Smithkline Beecham Corp. Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
JP2003516314A (ja) * 1999-09-17 2003-05-13 スミスクライン・ビーチャム・コーポレイション ライノウイルス感染症におけるｃｓａｉｄの使用
JP2003514900A (ja) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
WO2001038313A1 (en) 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p39 kINASE INHIBITORS
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6673818B2 (en) 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
US7473695B2 (en) * 2001-10-22 2009-01-06 Mitsubishi Tanabe Pharma Corporation 4-imidazolin-2-one compounds
EP1707205A2 (en) 2002-07-09 2006-10-04 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20050009931A1 (en) * 2003-03-20 2005-01-13 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20050004098A1 (en) * 2003-03-20 2005-01-06 Britten Nancy Jean Dispersible formulation of an anti-inflammatory agent
RU2325189C2 (ru) * 2003-03-20 2008-05-27 Фармация Корпорейшн Способ и фармацевтическая композиция для доставки противовоспалительного средства
US7105467B2 (en) * 2003-07-08 2006-09-12 Pharmacore, Inc. Nickel catalyzed cross-coupling reactions between organomagnesium compounds and anisole derivatives
US7105707B2 (en) * 2003-12-17 2006-09-12 Pharmacore, Inc. Process for preparing alkynyl-substituted aromatic and heterocyclic compounds
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US20080119498A1 (en) * 2004-12-06 2008-05-22 Masatomo Kato Therapeutic Agent for Pruritus Comprising P38 Map Kinase Inhibitor as the Active Ingredient
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
JP2007145819A (ja) * 2005-10-28 2007-06-14 Tanabe Seiyaku Co Ltd 医薬組成物
WO2007056016A2 (en) * 2005-11-02 2007-05-18 Kemia, Inc. Bisamide cytokine inhibitors
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
EP2799537B1 (en) 2011-12-28 2021-09-22 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
CA2928626C (en) 2013-11-14 2023-03-14 The Doshisha Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
CA3209491A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2748119A (en) 1954-06-23 1956-05-29 Searle & Co 6-furyl and 6-thienyl derivatives of 4-trifluoromethyl-2-pyrimidinamines
US3557114A (en) 1968-12-23 1971-01-19 Merck & Co Inc 1-substituted-3-(2-pyrimidinyl) imidazolium salts
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3940486A (en) 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US3929807A (en) 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US4058614A (en) 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4199592A (en) 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
CA1175431A (en) 1980-07-25 1984-10-02 Alfred Sallmann Tri-substituted imidazole derivatives, processes for their manufacture, pharmaceutical preparations containing them, and their use
US4503065A (en) 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4565875A (en) 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4686231A (en) 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IL83467A0 (en) 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
ZA919797B (en) 1990-12-13 1992-10-28 Smithkline Beecham Corp Bicyclo-5,6-dihydro-7h-pyrrolo-1,20-imidazol-7-ols and 7-ones
KR930703321A (ko) 1990-12-13 1993-11-29 스튜어트 알. 슈터 신규한 사이토킨 억제성 소염 의약
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
MX9300141A (es) 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5670527A (en) * 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
AU7629594A (en) 1993-07-21 1995-02-20 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
PL179417B1 (en) 1993-10-01 2000-09-29 Novartis Ag Pharmacologically active derivatives of pyridine and methods of obtaining them
PT672042E (pt) 1993-10-01 2006-08-31 Novartis Ag Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
US5612340A (en) 1993-10-01 1997-03-18 Ciba-Geigy Corporation Pyrimidineamine derivatives and processes for the preparation thereof
NZ302117A (en) 1995-01-12 1999-10-28 Smithkline Beecham Corp 1-cycloalkyl or cycloalkylalkyl 4,5-trisubstituted imidazole derivatives and medicaments
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
ZA97175B (en) 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
WO1997025047A1 (en) 1996-01-11 1997-07-17 Smithkline Beecham Corporation Novel cycloalkyl substituded imidazoles
US5756499A (en) 1996-01-11 1998-05-26 Smithkline Beecham Corporation Substituted imidazole compounds
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
JP2000507558A (ja) 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
WO1997035855A1 (en) 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
WO1998022109A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists

Also Published As

Publication number Publication date
EP0889726B1 (en) 2004-09-15
AP9700912A0 (en) 1997-01-31
AU715315B2 (en) 2000-01-20
HUP9901233A2 (hu) 2000-04-28
IL125224A0 (en) 1999-03-12
BR9708149A (pt) 1999-07-27
TR199801350T2 (xx) 1998-10-21
DE69730704T2 (de) 2005-09-22
NZ330889A (en) 2000-03-27
EP0889726A4 (en) 1999-07-21
JP2000503304A (ja) 2000-03-21
UY24434A1 (es) 1997-06-06
CN1213305A (zh) 1999-04-07
WO1997025048A1 (en) 1997-07-17
AU2242597A (en) 1997-08-01
ATE276248T1 (de) 2004-10-15
ZA97173B (en) 1997-07-18
DE69730704D1 (de) 2004-10-21
ID18759A (id) 1998-05-07
ES2229335T3 (es) 2005-04-16
NO983182L (no) 1998-09-09
PL327939A1 (en) 1999-01-04
CZ218198A3 (cs) 1999-09-15
MA24055A1 (fr) 1997-10-01
MX9805628A (es) 1998-11-29
US6329526B1 (en) 2001-12-11
EP0889726A1 (en) 1999-01-13

Similar Documents

Publication Publication Date Title
AR005434A1 (es) Imidazoles sustituidos por cicloalquilos, un procedimiento para su preparacion, composicion farmaceutica que los comprende, uso de los mismos parala manufactura de un medicamento.
UY26253A1 (es) Derivados del triazol y del imidazol
RU2328486C2 (ru) Производные 2-пиридона в качестве ингибиторов нейтрофильной эластазы
HRP20021023B1 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
DK0424059T3 (da) Anvendelse af substituerede imidazoler
RU2291860C3 (ru) Производные 2-оксо-1-пирролидина, способ их получения и применения
AR020558A1 (es) Un derivado de acido pirazolcarboxilico, su utilizacion, un procedimiento para su preparacion, composiciones farmaceuticas que lo contieneny compuestos utiles como intermediarios para prepararlo
NO20035210L (no) 2-anilino-pyrimidinderivater som cyklinavhengige kinaseinhibitorer
ES2164920T3 (es) Nuevos derivados heterociclicos y uso medicinal de los mismos.
MXPA06013534A (es) Compuesto de cinamida.
NO20045120L (no) Triazolderivater som takykininreseptorantagonister
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
NO970349D0 (no) Forbindelser som er anvendbare som antiproliferative midler og GARFT inhibitorer
RS51200B (sr) (imidazol-1-il-metil)-piridazin kao blokator nmda receptora
HK1071366A1 (en) Compounds which inhibit the release of inflammatory cytokines
DOP2009000106A (es) Compuestos de pirazol y triazol sustituídos como inhibidores de ksp
UY24504A1 (es) Dihidrato de eprosartano y un procedimiento para su produccion y formulacion
PE20040698A1 (es) Derivados de isoindolina
KR870003995A (ko) 신규 화합물의 제조방법
ES2127789T3 (es) Derivados de 1,2,4-triazol 4-sustituidos.
MX9203711A (es) Derivados de imidazol y composiciones farmaceuticas que los contienen.
EE05035B1 (et) 1-[fenüül-(8-kinolinüül)metüül]piperasiini derivaadid ning nende kasutamine meditsiinis
CO4920224A1 (es) Compuestos de pirrolidinil y pirrolinil etilamina como agonistas kappa
AR032894A1 (es) Compuestos imidazoles sustituidos, composicion farmaceutica, metodo para su preparacion y el uso de los mismos para la manufactura de medicamentos como agonistas o antagonistas de h1 y h3 de histamina.
MX9202647A (es) Derivados de benzimidazol, metodo para la produccion de los mismo, fungicidas que contienen los mismos como ingrediente activo y compuestos intermedidos de los mismos.